|
Neuvorstellung: Invitae - NTVA: Invitae More Than Doubles Annual Volume and Revenue Year-Over-Year, Delivering 117% in Revenue Growth Driven by 102% Growth in Volume in 2018 PR Newswire - Tue Feb 19, 3:05PM CST Invitae Corporation (NYSE:NVTA), a leading genetics company, today announced financial and operating results for the fourth quarter and full year ended December 31, 2018. https://mma.prnewswire.com/media/823911/Invitae_Q4_18_Data_I… "In just five years, we have provided more than half a million people with high quality, comprehensive, affordable genetic information to inform healthcare decisions across all stages of life," said Sean George, co-founder and chief executive officer of Invitae. "We believe we're on an unprecedented growth trajectory that translates into better health decisions informed by genetic information. Our seemingly audacious mission to bring genetics into mainstream medicine and benefit people through all stages of life, is coming into clear focus - not only in diagnosing disease, but in helping people as they think about starting a family or informing those who want to be proactive about their health." Full Year and Fourth Quarter 2018 Financial Results -- Increased test volume by 102% year-over-year: -- Accessioned approximately 303,000 samples in 2018, including approximately 87,000 samples in the fourth quarter, which exceeded the increased 2018 guidance of more than 285,000 samples expected in 2018 -- Increased revenue by 117% year-over-year: -- Generated revenue of $147.7 million in 2018, including $45.4 million in the fourth quarter, which exceeded the increased 2018 guidance range of $140-145 million expected in 2018 -- Includes $1.9 million in payments from Medicare for Lynch syndrome analysis -- Decreased cost of goods sold (COGS) per sample by 24% year-over-year: -- Drove down COGS per sample to $243 in the fourth quarter -- Improved gross profit by 274% year-over-year: -- Achieved gross profit of $67.6 million in 2018, including $24.2 million in the fourth quarter -- Reported 46% gross margins in 2018, including 53% gross margins in the fourth quarter Total operating expenses, which excludes cost of revenue, for the full year 2018 were $190.2 million compared to $139.4 million in 2017. Operating expenses for the fourth quarter of 2018 were $50.1 million compared to $43.2 million in the fourth quarter of 2017. For the full year 2018, net loss was $129.4 million, or a $1.94 net loss per share compared to a net loss of $123.4 million, or a $2.65 net loss per share, for the full year 2017. For the fourth quarter of 2018, Invitae reported a net loss of $29.8 million, or a $0.40 net loss per share, compared to a net loss of $40.5 million in the fourth quarter of 2017, or a $0.78 net loss per share. At December 31, 2018, cash, cash equivalents, restricted cash, and marketable securities totaled $131.9 million. Net increase in cash, cash equivalents and restricted cash was $100.7 million in 2018 and $11.7 million for the fourth quarter, and cash burn was $97.6 million in 2018 and $17.0 million for the fourth quarter. Corporate and Scientific Highlights -- Published data in the in Journal of Clinical Oncology by researchers from the TME Breast Care Network and Invitae showing that current guidelines for genetic testing of breast cancer patients miss as many patients with pathogenic variants as they find. -- Partnered with researchers at Tulane Cancer Center on the largest study to date on the genetics of prostate cancer. Published in JAMA Oncology, the study found that guidelines for genetic testing at the time of the study missed a substantial number of patients, suggesting broader genetic testing for prostate cancer is warranted. -- Announced plans to launch a new patient-initiated testing channel in the second quarter of 2019, which will allow consumers to initiate a comprehensive genetic test themselves, making it easier than ever for patients to get medically actionable genetic information that can inform health decisions. -- Announced the launch of non-invasive prenatal screening (NIPS) as our most recent addition to Invitae's comprehensive women's health genetic testing services, providing patients with easier access to affordable genetic testing in early pregnancy. -- Continued the expansion of our network, signing 11 new partnerships with biopharma companies, health systems, and major cancer centers since the beginning of the fourth quarter. About Invitae Invitae Corporation (NYSE:NVTA) is a leading genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com. financials: https://www.marketscreener.com/INVITAE-CORP-20708461/financi…" target="_blank" rel="nofollow ugc noopener"> https://www.marketscreener.com/INVITAE-CORP-20708461/financi… |
|
| aus der Diskussion: | Gewinnerbranchen der Jahre 2006 bis 2040 |
| Autor (Datum des Eintrages): | clearasil (03.03.19 12:47:57) |
| Beitrag: | 85,078 von 94,068 (ID:60008156) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |